ADVERTISEMENT
Improved Healing with RNA-based Therapy
miRagen Therapeutics, Inc (Boulder, CO), a clinical-stage biopharmaceutical company specializing in RNA-targeted therapy, shared its preclinical study data on MFG-110 at the Symposium of Advanced Wound Care Spring held April 25-29, 2018. In a porcine model, the miR-92 inhibitor increased vascularization within the wound bed as well as increased formation of new connective tissue and microscopic blood vessels. In addition, there was evidence of accelerated wound healing in the majority of treated animals at all dose levels studied.
The product is currently the subject of a Phase 1 clinical trial assessing its safety and tolerability following systemic dosing in collaboration with Servier (Neuilly-sur-Seine, France), an independent international pharmaceutical company.
Visit www.miragen.com for more information.
Advertisement
Reimbursement Library From A to Z
Subscribe and never miss an article!
Advertisement
Coping With COVID-19
Advertisement